



LABORATORY REPORT

Example Client, XYZ123
1234 Warde Road
Ann Arbor MI 48108

EXAMPLE, REPORT W
WX0000003827 M 07/08/1978 45 Y

Referral Testing

Collected: 09/25/2023 11:45 Received: 09/25/2023 11:45

Table with 6 columns: Test Name, Result, Flag, Ref-Ranges, Units, Site. Row 1: Interleukin 28B (IL28B) Variant (rs12979860), Varies, See Below, WMMR

Table with 4 columns: Test, Result, Flag, Ref Range. Row 1: IL28B Genotype, C/C. Row 2: IL28B Phenotype, Increased sustained virologic response

Interpretation
This patient has a genotype that has been associated with an approximately 2- to 3-fold greater rate of sustained virologic response (SVR) in HCV genotype 1-infected individuals treated with combined pegylated-interferon and ribavirin therapy as compared to either the CT or TT genotypes.

Method
Genotyping is performed using a PCR-based 5'-nuclease assay. Fluorescently labeled detection probes anneal to the target DNA. PCR is used to amplify the segment of DNA that contains the polymorphism.

Disclaimer
Targeted variant analysis is performed for the IL28B-related rs12979860 (c.-3180G>A). Note that IL28B is now known as IFNL3. This test will not detect other IL28B (IFNL3) variants.

The SNP in IL28B is used to predict response to pegylated-interferon and ribavirin combination therapy for hepatitis C.

LAB: L - LOW, H - HIGH, AB - ABNORMAL, C - CRITICAL, . - NOT TESTED



LABORATORY REPORT

Example Client, XYZ123
1234 Warde Road
Ann Arbor MI 48108

EXAMPLE, REPORT W
WX0000003827 M 07/08/1978 45 Y

Referral Testing

Collected: 09/25/2023 11:45 Received: 09/25/2023 11:45

<u>Test Name</u>	<u>Result</u>	<u>Flag</u>	<u>Ref-Ranges</u>	<u>Units</u>	<u>Site</u>
	C, genotype 1 infections. IL28B is only one factor that can influence response rates to pegylated-interferon and ribavirin combination therapy.				

CAUTIONS:

Samples may contain donor DNA if obtained from patients who have recently received non-leukoreduced blood transfusions or allogeneic hematopoietic stem cell transplantation. Results from samples obtained under these circumstances may not accurately reflect the recipient's genotype. For individuals who have received blood transfusions, the genotype usually reverts to that of the recipient within 6 weeks. For individuals who have received allogeneic hematopoietic stem cell transplantation, a pretransplant DNA specimen is recommended for testing.

For liver transplant patients, the IL28B genotype of the recipient and the donor are independent predictors of sustained virologic response with combined pegylated-interferon and ribavirin therapy.

Reviewed by

Laboratory Notes

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

Test(s) performed at
Mayo Clinic Laboratories - Rochester Main Campus
200 First Street SW, Rochester, MN 55905
Lab Director William G. Morice M.D., Ph.D.

Performing Site:

WMMR: MAYO CLINICAL LABS 3050 Superior Drive NW Rochester MN 55901

Reported Date: 2023.09.25 11:45

LAB: L - LOW, H - HIGH, AB - ABNORMAL, C - CRITICAL, . - NOT TESTED

F325000042
WX0000003827

Ordered By: KAJAL SITWALA, MD, PhD
WX00000000002365

Kajal V. Sitwala, MD, PhD - Medical Director

Form: MM RL1

Printed D&T: 09/25/23 11:45

PAGE 2 OF 2